Sverker Hasselblom

671 total citations
25 papers, 494 citations indexed

About

Sverker Hasselblom is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Sverker Hasselblom has authored 25 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 6 papers in Neurology. Recurrent topics in Sverker Hasselblom's work include Lymphoma Diagnosis and Treatment (18 papers), Viral-associated cancers and disorders (8 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Sverker Hasselblom is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Viral-associated cancers and disorders (8 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Sverker Hasselblom collaborates with scholars based in Sweden. Sverker Hasselblom's co-authors include Per‐Ola Andersson, Herman Nilsson‐Ehle, Börje Ridell, Ulrika Hansson, Margrét Sigurðardóttir, Anders Bergström, Klas Norrby, Tor Ekman, Hans Wedel and Annika Linde and has published in prestigious journals such as Blood, British Journal of Haematology and Journal of Internal Medicine.

In The Last Decade

Sverker Hasselblom

24 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sverker Hasselblom Sweden 14 320 209 145 115 103 25 494
Manuel F. Rosado United States 10 333 1.0× 249 1.2× 87 0.6× 97 0.8× 58 0.6× 14 491
Parth Desai United States 12 295 0.9× 289 1.4× 58 0.4× 189 1.6× 91 0.9× 52 576
Wouter J. Plattel Netherlands 12 313 1.0× 223 1.1× 103 0.7× 61 0.5× 56 0.5× 49 418
Peter Kamper Denmark 11 346 1.1× 267 1.3× 189 1.3× 49 0.4× 65 0.6× 41 532
Ken Ohmachi Japan 13 403 1.3× 342 1.6× 91 0.6× 211 1.8× 63 0.6× 46 599
F Loong China 11 386 1.2× 282 1.3× 154 1.1× 69 0.6× 168 1.6× 19 612
Nilima Parry‐Jones United Kingdom 13 318 1.0× 169 0.8× 100 0.7× 319 2.8× 95 0.9× 21 500
Tariq Muzzafar United States 14 220 0.7× 152 0.7× 79 0.5× 176 1.5× 95 0.9× 34 507
Johan Linderoth Sweden 12 408 1.3× 276 1.3× 97 0.7× 171 1.5× 125 1.2× 24 562

Countries citing papers authored by Sverker Hasselblom

Since Specialization
Citations

This map shows the geographic impact of Sverker Hasselblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sverker Hasselblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sverker Hasselblom more than expected).

Fields of papers citing papers by Sverker Hasselblom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sverker Hasselblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sverker Hasselblom. The network helps show where Sverker Hasselblom may publish in the future.

Co-authorship network of co-authors of Sverker Hasselblom

This figure shows the co-authorship network connecting the top 25 collaborators of Sverker Hasselblom. A scholar is included among the top collaborators of Sverker Hasselblom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sverker Hasselblom. Sverker Hasselblom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fagman, Henrik, et al.. (2021). Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients. Leukemia & lymphoma. 62(10). 2360–2373. 3 indexed citations
3.
Eloranta, Sandra, Sara Ekberg, Gunilla Enblad, et al.. (2019). Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden. Blood. 134(Supplement_1). 399–399. 6 indexed citations
4.
Fagman, Henrik, Gunilla Enblad, Ulf‐Henrik Mellqvist, et al.. (2019). Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype. Blood. 134(Supplement_1). 3967–3967. 2 indexed citations
5.
Ekberg, Sara, Mats Jerkeman, Per‐Ola Andersson, et al.. (2018). Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma. American Journal of Hematology. 93(8). 1020–1028. 19 indexed citations
6.
Smedby, Karin E., Sara Ekberg, Per Andersson, et al.. (2017). LONG‐TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION‐BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA. Hematological Oncology. 35(S2). 127–128. 5 indexed citations
7.
Pedersen, Anders, Sverker Hasselblom, Herman Nilsson‐Ehle, et al.. (2016). Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients – a pilot study. Leukemia & lymphoma. 57(8). 1814–1822. 16 indexed citations
8.
Rüetschi, Ulla, Sverker Hasselblom, Herman Nilsson‐Ehle, et al.. (2015). SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. PubMed. 2015. 1–12. 15 indexed citations
9.
Rüetschi, Ulla, et al.. (2012). Can Global Protein Expression Profiling Determine Prognosis in Diffuse Large B-Cell Lymphoma?. Blood. 120(21). 1537–1537. 1 indexed citations
10.
Hasselblom, Sverker, Monica Sender, Catharina Lewerin, et al.. (2011). Improved outcome for very elderly patients with diff use large B-cell lymphoma in the immunochemotherapy era. Leukemia & lymphoma. 53(3). 394–399. 20 indexed citations
11.
Hasselblom, Sverker, Börje Ridell, Margrét Sigurðardóttir, et al.. (2008). Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leukemia & lymphoma. 49(8). 1501–1509. 36 indexed citations
12.
Hasselblom, Sverker, Ulrika Hansson, Margrét Sigurðardóttir, et al.. (2008). Expression of CD68+ tumor‐associated macrophages in patients with diffuse large B‐cell lymphoma and its relation to prognosis. Pathology International. 58(8). 529–532. 63 indexed citations
13.
Hasselblom, Sverker, et al.. (2007). The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma. British Journal of Haematology. 137(4). 364–373. 58 indexed citations
14.
Hasselblom, Sverker, Börje Ridell, Herman Nilsson‐Ehle, & Per‐Ola Andersson. (2007). The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study. Leukemia & lymphoma. 48(4). 736–745. 36 indexed citations
15.
Junevik, Katarina, et al.. (2006). The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL). Annals of Hematology. 86(2). 89–94. 9 indexed citations
16.
Apelgren, Peter, et al.. (2006). Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. Leukemia & lymphoma. 47(12). 2505–2516. 13 indexed citations
17.
Hasselblom, Sverker, Annika Linde, & Börje Ridell. (2004). Hodgkin's lymphoma, Epstein–Barr virus reactivation and fatal haemophagocytic syndrome. Journal of Internal Medicine. 255(2). 289–295. 20 indexed citations
18.
Hasselblom, Sverker, et al.. (2004). Testicular lymphoma A Retrospective, Population-based, Clinical and Immunohistochemical Study. Acta Oncologica. 43(8). 758–765. 50 indexed citations
19.
Lapidus, Leif, et al.. (2002). Home Treatment of Deep Vein Thrombosis. Pathophysiology of Haemostasis and Thrombosis. 32(2). 59–66. 21 indexed citations
20.
Johansson, Bertil, Jonas Waldenström, Sverker Hasselblom, & Felix Mitelman. (1995). Waldenström's macroglobulinemia with the AML/MDS-associated t(1;3)(p36;q21).. PubMed. 9(7). 1136–8. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel F. Rosado Breakdown of academic impact, for papers by Parth Desai Breakdown of academic impact, for papers by Wouter J. Plattel Breakdown of academic impact, for papers by Peter Kamper Breakdown of academic impact, for papers by Ken Ohmachi Breakdown of academic impact, for papers by F Loong Breakdown of academic impact, for papers by Nilima Parry‐Jones Breakdown of academic impact, for papers by Tariq Muzzafar Breakdown of academic impact, for papers by Johan Linderoth
Rankless by CCL
2026